[cs_content][cs_section parallax=”false” separator_top_type=”none” separator_top_height=”50px” separator_top_angle_point=”50″ separator_bottom_type=”none” separator_bottom_height=”50px” separator_bottom_angle_point=”50″ style=”margin: 0px;padding: 20px 0px;”][cs_row inner_container=”true” marginless_columns=”false” style=”margin: 0px auto;padding: 0px;”][cs_column fade=”false” fade_animation=”in” fade_animation_offset=”45px” fade_duration=”750″ type=”1/3″ style=”padding: 10px 0px 0px;”][x_image type=”none” src=”http://beatcc2018.wpengine.com/wp-content/uploads/2017/05/Dr.-Sholler-with-Patient_foundation.jpg” alt=”” link=”false” href=”#” title=”” target=”” info=”none” info_place=”top” info_trigger=”hover” info_content=””][x_image type=”none” src=”http://beatcc2018.wpengine.com/wp-content/uploads/2017/05/hdvch.png” alt=”” link=”false” href=”#” title=”” target=”” info=”none” info_place=”top” info_trigger=”hover” info_content=””][x_line style=”border-top-width: 1px;”][/cs_column][cs_column fade=”false” fade_animation=”in” fade_animation_offset=”45px” fade_duration=”750″ type=”2/3″ style=”padding: 0px;”][cs_text class=”cs-ta-left”]

Dr Giselle Sholler

Helen DeVos Children’s Hospital

[/cs_text][cs_text]Dr. Sholler is the Chair of Beat Childhood Cancer (formerly NMTRC), the Endowed Director of the Haworth Family Innovative Therapeutics Clinic, and Director of Pediatric Oncology Research at Helen DeVos Children’s Hospital.

Appointments: (616) 267-0334 to schedule.

100 Michigan St. NE MC272
Grand Rapids, MI 49503
Phone: (616) 267-0335
E-mail: giselle.sholler@helendevoschildrens.org[/cs_text][/cs_column][/cs_row][/cs_section][cs_section parallax=”false” separator_top_type=”none” separator_top_height=”50px” separator_top_angle_point=”50″ separator_bottom_type=”none” separator_bottom_height=”50px” separator_bottom_angle_point=”50″ style=”margin: 0px;padding: 0 0px 45px;”][cs_row inner_container=”true” marginless_columns=”false” style=”margin: 0px auto;padding: 0px;”][cs_column fade=”false” fade_animation=”in” fade_animation_offset=”45px” fade_duration=”750″ type=”1/1″ style=”padding: 0px;”][x_tab_nav type=”three-up” float=”top”][x_tab_nav_item title=”Background” active=”true”][x_tab_nav_item title=”Education” active=”true”][x_tab_nav_item title=”Selected Publications” active=”false”][/x_tab_nav][x_tabs][x_tab active=”true”]Dr Sholler is currently a Pediatric Oncologist and Endowed Haworth Family Director of the Innovative Therapeutics Clinic and Director of Pediatric Oncology Research, and Head of the Pediatric Oncology Translational Research Laboratory at Helen DeVos Children’s Hospital. She is Associate Professor at Michigan State University College of Human Medicine. The support and infrastructure of these institutions and their dedication to children creates an environment where innovative research and therapies can be brought forward to children.

As the chair and lead investigator of Beat Childhood Cancer (formerly NMTRC) and through preclinical work done within her laboratory, Dr Sholler successfully opens new Phase I and II trials for neuroblastoma and medulloblastoma patients, as well as Molecular Guided Therapy trials using precision medicine based on genomic analysis of pediatric tumors. Beat Childhood Cancer is a collaborative team of over 40 distinguished universities and children’s hospitals that have joined together to offer a national network of clinical trials. Dr Sholler is committed to developing novel therapies and to working closely with collaborating investigators to share and perform innovative laboratory research and to continue to open clinical trials across the nation. Their strong track record of working closely with esteemed investigators studying neuroblastoma in this collaborative environment provides the constant availability of innovative perspectives that drives her research forward and ultimately makes a difference in the daily lives of children living with cancer.[/x_tab][x_tab active=”true”]

[/x_tab][x_tab active=”false”]Lozier AM, Rich ME, Grawe AP, Peck AS, Zhao P, Ting-Tung Chang, Bond JP, Saulnier Sholler G, Targeting ornithine decarboxylase reverses the LIN28/Let-7 axis and inhibits glycolytic metabolism in neuroblastoma. Oncotarget 6(1): 196-206 (2014)

Saulnier Sholler GL, Bond JP, Bergendahl G, Dutta A, Dragon J, Neville K, Ferguson W, Roberts W, Eslin D, Kraveka J, Kaplan J, Mitchell D, Parikh N, Merchant M, Ashikaga T, Hanna G, Lescault PJ, Siniard A, Corneveaux J, Huentelman M, Trent J.  Feasibility of implementing molecular-guided therapy for the treatment of patients with relapsed or refractory neuroblastoma.  Cancer Med. 2015 Feb 26. doi: 10.1002/cam4.436. [Epub ahead of print]

Saulnier Sholler G, Gerner EW, Bergendahl G, MacArthur RB, Vander Werff A, Ashikaga T, Bond JP,  Ferguson W, Roberts W, Wada RK, Eslin D, Kraveka JM, Kaplan J, Mitchell D, Parikh NS, Neville K, Sender L, Higgins T, Kawakita M, Hiramatsu K, Moriya S, Bachmann AS, A Phase I Trial of DFMO Targeting Polyamine Addiction in Patients with Relapsed/Refractory Neuroblastoma, PlosONE May 2015

Sun Y, Sholler GS, Shukla GS, Pero SC, Carman CL, Zhao P, Krag DN Autologous antibodies that bind neuroblastoma cells, J Immunol Methods. 2015 Jul 23. pii: S0022-1759(15)30025-9. doi: 10.1016/j.jim.2015.07.009. [Epub ahead of print]

Mitchell D, Bergendahl G, Ferguson W, Roberts W, Higgins T, Ashikaga T, DeSarno M, Kaplan J, Kraveka J, Eslin D, Werff AV, Hanna GK, Sholler G, A Phase 1 Trial of TPI 287 as a Single Agent and in Combination With Temozolomide in Patients with Refractory or Recurrent Neuroblastoma or Medulloblastoma, Pediatr Blood Cancer. 2016 Jan;63(1):39-46. doi: 10.1002/pbc.25687. Epub 2015 Jul 31

Maser T, Rich M, Hayes D, Zhao P, Nagulapally AB, Bond J, Saulnier Sholler G. Tolcapone induces oxidative stress leading to apoptosis and inhibition of tumor growth in Neuroblastoma, Cancer Med. 2017 Apr 21. doi: 10.1002/cam4.1065. [Epub ahead of print][/x_tab][/x_tabs][/cs_column][/cs_row][/cs_section][/cs_content]